Associated Papers
Comparative outcome and prognostic factor analysis among MDS/AML patients with TP53 mutations, snps, and wild type.
Yang X et al.
Human Genomics, 2025
40877983 (PubMed )
Supplement: 40246_2025_792_MOESM2_ESM.xlsx › Table_S8
Deep CRISPR mutagenesis characterizes the functional diversity of TP53 mutations.
Funk JS et al.
Nature Genetics, 2025
39774325 (PubMed )
Supplement: 41588_2024_2039_MOESM5_ESM.xlsx › SuppFig6
Somatic Mutation Profiling in the Liquid Biopsy and Clinical Analysis of Hereditary and Familial Pancreatic Cancer Cases Reveals KRAS Negativity and a Longer Overall Survival.
Earl J et al.
Cancers, 2021
Change in mutation frequency at a TP53 hotspot during culture of ENU-mutagenised human lymphoblastoid cells.
Watanabe M et al.
Mutagenesis, 2019
Comprehensive identification of long noncoding RNAs in colorectal cancer.
James de Bony E et al.
Oncotarget, 2018
29963224 (PubMed )
Supplement: oncotarget-09-27605-s005.xlsx › Sheet1
Modelling mutational landscapes of human cancers in vitro.
Olivier M et al.
Scientific Reports, 2014
24670820 (PubMed )
Supplement: srep04482-s1.pdf
Select a paper to view details